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Aging, Cerebrovascular Burden, 
and Cognitive Decline
Kyoungjoo Cho
Abstract
Brain function is supported by the cerebrovascular system, and changes in vas-
cular phenotype and function through aging process make the brain more suscep-
tible to neurodegenerative diseases, particularly cognitive decline. Correspondingly, 
the incidence of dementia and the prevalence of neurodegenerative diseases have 
also increased. In aging, the vessels have been exposed to the inflammatory state 
by harmful factors referred to as the senescence-associated secretory phenotype 
(SASP). Aging is a complex process that is associated with accumulated cellular 
stresses and an increased stress response. The aging in the brain includes structural 
and functional changes, which cause brain pathologies in the elderly. Particularly, 
damaged neurovascular event can be a consequent trigger in the pathology of 
vascular cognitive impairment. This chapter introduces the current knowledge on 
cognitive decline according to cerebrovascular aging relevant to endothelial senes-
cence and the changes in the SASPs.
Keywords: aging, cerebrovascular, cognitive impairment, senescence-associated 
secretory phenotype, endothelial cells
1. Introduction
Aging is a complex process that is associated with an accumulation of the effects 
of cellular stresses and an increased stress response. The aging in the brain includes 
structural and functional changes, which together cause brain pathologies in the 
elderly. These changes are also thought to be critical risk factors in the develop-
ment of cognitive disorders [1, 2]. It is well known that the cerebrovascular system 
supports brain function [3]. Vascular phenotypic and functional changes caused by 
aging make the brain more susceptible to neurodegenerative diseases, particularly 
to cognitive decline [4]. Dysregulation of cerebral blood flow (CBF) is one factor in 
the pathogenesis of vascular cognitive impairment (VCI) [5]. However, definition, 
diagnostic criteria, and treatments for VCI have not been firmly established. Thus, 
strategies in translational medicine and the clinical approach to VCI patients and 
the current aged society need to be established. This is because according to the 
World Alzheimer Report 2015, it was estimated that 46.8 million people worldwide 
suffer from dementia, and this number is expected to increase to 74.7 million by 
2030 and 131.5 million by 2050 [6]. The report also stated that the incidence of 
dementia, including Alzheimer’s disease (AD) and vascular dementia (VaD), will 
increase by 45%. As a result of the increase in the size of the aging population, the 
incidence of dementia and the onset or prevalence of neurodegenerative diseases 
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are increasing. These diseases have become important social concerns and represent 
both a current and a future social and economic burden.
In the aging process, age-related cerebrovascular dysfunction results from 
multiple pathophysiological changes. The first of them is oxidative stress and 
inflammation. Excessive oxidative stress is well known to contribute to vascular 
aging in both animals [4, 7–10] and humans [11, 12]. It is an overproduction of 
reactive oxygen species (ROS) rather than accumulation of ROS. In cellular senes-
cence, inflammatory mediators such as chemokines and cytokines are secreted in an 
autocrine or paracrine manner. This is often referred to as the senescence-associated 
secretory phenotype (SASP) [13–15]. The second is the narrowing of the vascular 
lumen caused by atherosclerotic plaques, which is referred to as atherosclerosis in 
large vessels or arteriosclerosis in small vessels [16–18]. Technically a further factor 
is endothelial cell senescence induced by the SASP in the aging process. This arises 
as a result of the action of pro-inflammatory cytokines such as interleukin (IL)-1 
and IL-6 [19]. Under aging, atherosclerotic plaques are prone to arise in the human 
aorta and coronary arteries, which contain senescent endothelial cells [20]. The 
senescent phenotypes of endothelial cells can be physiologically classified as having 
either an anti-inflammatory phenotype or a pro-inflammatory senescent phenotype 
[21]. Recently, numerous studies have focused on the status of the immune system 
during aging [22–24]. This chapter introduces the current knowledge about cogni-
tive decline according to cerebrovascular aging relevant to cellular senescence and 
the changes in the SASPs. It also provides approaches on how senescent vessels 
exposed to the SASP enhance age-related cerebrovascular degeneration and vascu-
lar damage-derived cognitive impairment.
2. Aging and vessels
Cellular senescence is the state in which normal cells cease to divide. It can be 
thought of as a type of programmed cell cycle arrest. The senescent cells go through 
changes in gene expression and secretion of soluble factors in response to excessive 
stresses [25]. The secreted soluble factors from senescent cells are referred to as the 
SASP [26–28]. The SASP includes interleukins (IL) and chemokines such as IL-1, 
IL-6, IL-8, monocyte chemoattractant protein (MCP)-2, and macrophage inflam-
matory protein (MIP)-1 [29]. In addition, nitric oxide, growth factors, and several 
matrix metalloproteinases have also been identified in the SASP [14]. Several stud-
ies have reported that SASP factors have roles in inducing normal cells to acquire 
a senescent phenotype and can act in a paracrine manner to affect the activity of 
other nearby cells [30]. This might suggest that SASP factors do not merely arise as 
a result of cell senescence but could rather act to promote the senescence phenotype 
in normal cells.
Although it still remains equivocal whether neurodegenerative diseases arise as 
a result of, or from, aging-related changes, it is clear, however, that the prevalence 
of neurodegenerative diseases that show a cognitive decline is positively associated 
with aging. Increases in oxidative stress and inflammation in response to aging trig-
ger cellular senescence and the appropriate downstream responses. A series of these 
insults can aggravate age-related or neurodegenerative pathogenesis with several 
vascular diseases [31].
2.1 Endothelium
The endothelium is one of the vessel constituents and is important in vascular 
structure because of its high versatility. The endothelium has multifunctional 
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roles in maintaining blood fluidity and metabolic homeostasis. The features are 
important in regulating the delivery of water and nutrients through the whole body 
[32]. The endothelium also plays an important role in the resolution of inflam-
matory responses. Morphological and functional changes in the endothelium are 
also involved in the development of numerous pathological disorders [33, 34]. 
Endothelial cells are located in the inner layer of the vasculature and can come 
into contact with blood-containing macrophages. Therefore, endothelial cells are 
the first target of cytokines circulating in the blood. Simultaneously, endothelial 
cells also secrete pro-inflammatory cytokines, such as IL-1, IL-6, IL-8, IL-15, 
MCP-1, and tumor necrosis factor (TNF)-α [29]. In fact, endothelial cell-derived 
pro-inflammatory cytokines and chemokines are important in recruiting immune 
cells to the site and play a role in wound healing, angiogenesis, and inflammatory 
diseases. In addition to their inflammatory function, endothelial cells also produce 
pro-thrombotic mediators and cellular adhesion molecules (ICAM-1, intercellular 
adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1) and enhance the 
adhesion and transmigration of immune cells into underlying tissues. It has also 
been reported that senescent endothelial cells have reduced expression levels of 
nitric oxide (NO) as well as reduced expression levels and phosphorylation of 
endothelial NO synthase (eNOS) [35, 36].
It is well accepted that senescence in vascular endothelial cells is a common 
factor in various age-related diseases. Associated with aging, endothelial cells 
dynamically change the inflammatory phenotype to SASP [21]. A recent study has 
demonstrated that alterations in toll-like receptor (TLR) and TLR ligands during 
aging might determine the state of the inflammatory process [29]. Since endothelial 
cells are not immune cells, they cannot recognize foreign antigens via TLRs or pres-
ent antigens through MHC II molecules to T and B cells [37]. On the other hand, 
endothelial cells have been shown to upregulate the mRNA levels of TLR-2, TLR-4, 
TLR-7, TLR-8, TLR-9, and TLR-10 during aging [38]. Since aging is a chronic 
inflammatory condition in the lower level, nonimmune endothelial cells could play 
a role in controlling and maintaining immune homeostasis. Taken these reasons, 
endothelial cells could be a therapeutic target to allow for recovery of a disruption 
in immune homeostasis.
Endothelial cells derived from patients with severe coronary artery disease have 
also been shown to be mostly senescent endothelial cells with reduced levels of telo-
meric DNA-binding factor 1 (TRF1) and increased telomere oxidation [20]. When 
TRF1 was overexpressed in a cellular aging model, namely, human umbilical vein 
endothelial cells’ (HUVECs) passage for a long period of time, the telomere-associ-
ated DNA damage foci and the SASP were decreased [39, 40]. These results suggest 
that telomere dysfunction and the SASP occur prior to cellular senescence and 
induce vascular dysfunction following cardiovascular disease (CVD) development.
2.2 Atherosclerosis
Atherosclerosis and its associated clinical outcomes such as vascular stiffness 
are initiated and progressed through dysfunction in senescent endothelial cells 
[29]. During oxidation in the vessel, there are changes in its physicochemical 
properties including lipid charge, size, and content. Oxidized low-density lipid 
(oxLDL) becomes different from natural LDL. The oxLDL stimulates endothelial 
cells to induce the expression of adhesion molecules such as E-selectin and vascular 
cell adhesion molecule-1 (VCAM-1) on the surface of the artery [41]. Numerous 
senescent endothelial cells are detected in the aorta of the human with athero-
sclerotic plaques [42, 43]. The formation of atherosclerotic plaques is initiated by 
macrophages that infiltrate into the arterial intima in response to oxLDL present in 
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the vessel [69]. Lipid-laden foam cells become pro-inflammatory, and macrophages 
secrete pro-inflammatory cytokines. The recruited macrophages move into the 
artery, and consequently, the atherosclerotic plaque size and complexity are getting 
larger [44].
Atherosclerosis occurs following chronic exposure to cellular stressors. It has 
been reported that SASP can be restrained simply by inhibiting TNF-α without 
any transmission of senescence signals in an autocrine or paracrine manner [45]. 
Anti-TNF-α treatment has been demonstrated to physiologically reduce the non-
cell autonomous effects of SASP. In patients treated with adalimumab (Humira, 
a human monoclonal antibody against TNF-α), epigenetic modifications were 
triggered. The molecular mechanisms are identified as TNF-α signaling in senescent 
endothelial cells, which raises the possibility of therapeutic approaches for age-
associated diseases. In senescent human umbilical vein endothelial cells (HUVECs), 
the levels of miR-146a-5p and miR-126-3p show higher than younger HUVECs. 
Additionally, the levels of miR-146a-5p are increased in both senescent and young 
HUVECs following lipopolysaccharide (LPS) exposure, whereas the level of miR-
126-3p is decreased only in senescent HUVECs and is unchanged in young HUVECs 
[45]. This study also showed that changes in the levels of several microRNAs (miR-
NAs) do not arise as a result of just treatment with LPS or an anti-TNF-α antibody. 
These data suggest that some miRNAs work in an age-dependent manner in vessels 
and endothelial cells.
2.3 Vascular aging
From a classical perspective, the aged vasculature is viewed as having worsened 
vasodilation, arterial stiffness, remodeling of the extracellular matrix, intimal 
thickening, and endothelial cell dysfunction [46]. The effects of vascular aging 
have been explored extensively and have been attributed to the number of different 
causes with genome instability and mTOR being two of the major causes. Studies 
with mTOR-inhibiting drugs in vessels have shown that such drugs have a deleteri-
ous effect on endothelial function in patients who have advanced arterial aging and 
inserted coronary stents [47–49]. Compared to human studies, cultured endothelial 
cells have augmented anti-inflammatory effects to mTOR inhibitors with a dose-
dependent manner and have increased cytostatic effect [50]. It also showed that 
rapamycin, an mTOR inhibitor, induces the expression of PAI-1 in mice as well as 
in cultured endothelial cells [51]. When the Atg7 gene, one of the mediators of the 
autophagic process, is deleted in mice, vascular aging is accelerated [52]. In a mouse 
model of Hutchinson-Gilford progeria, autophagy is activated by AMPK activation 
and inhibition of mTOR [53]. These results showed that the mTOR–AMPK signal-
ing pathway might be a link to the regulation of autophagy in age-related diseases. 
Based on the results described above, it is hard to firmly establish that rapamycin 
plays a preventive role on cellular senescence.
Telomere shortening is known to be a hallmark of cellular senescence. Telomeres 
are significantly shorter in several endothelial cells and vascular smooth muscle 
cells (VSMCs), which is a clear marker of SASP in aged vasculature. The shortened 
telomeres in mouse vascular tissue have been shown to be sufficient to induce 
endothelial dysfunction [54], whereas human VSMCs still have a normal phenotype 
sustaining plaque stability regardless of telomere length [55]. Although telomere 
shortening is common in vascular aging and CVD, it remains unclear whether 
telomere shortening is sufficient to lead to cellular senescence and vascular degen-
eration in aged vessels [56].
In the patients with severe coronary artery disease, most of endothelial cells 
demonstrated the features of senescent endothelial cells that reduced levels of 
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telomeric DNA-binding factor 1 (TRF1) and increased telomere oxidation as men-
tioned above [20, 39, 40]. These results suggest that telomere dysfunction and the 
SASP occur prior to cellular senescence and induce vascular dysfunction following 
CVD development.
The causes of vascular aging and vascular aging-related phenotypes can be sum-
marized as follows:
i. Oxidative DNA damage: during aging, the onset of CVD led by changes 
in vascular endothelial cells results in an impairment of endothelium-
dependent vasodilation, an overproduction of pro-inflammatory and pro-
thrombotic factors, and an increase in oxidative stress [57]. In the human 
population, age is an important and independent risk factor for CVD [58].
ii. Telomere shortening: an association between telomere shortening and CVD 
risk factors has been found in atherosclerosis, arterial stiffness, type 1 and 
type 2 diabetes, and obesity [59–62].
iii. Genome instability: a failure in DNA damage repair occurs in cells and tis-
sues during the aging process [63].
3. Aging and cerebrovascular function
As aging progresses, cerebrovascular function declines which can increase the 
possibility for ischemic stroke, intracerebral hemorrhages (ICHs), microbleeds, and 
cognitive decline [64]. Healthy functional cerebral vessels can coordinate with CBF 
and appropriately supply blood to the brain [65]. However, cerebrovascular aging 
has the following features, which can lead to age-related cerebrovascular diseases: 
(i) endothelial senescence, (ii) oxidative stress and inflammation, (iii) microvascu-
lar rarefaction, (iv) arterial stiffness, (v) vascular lumen narrowness, and (vi) CBF 
reduction. Each feature according to cerebrovascular aging is described in detail in 
the following subsections.
3.1 Cerebral vasculature
Cerebral vessels play a critical role in mediating between the whole body and 
the brain by transporting molecules between the blood and brain [5]. The brain 
vasculature that supplies blood to the brain tissue consists of two blood supply 
systems. One is the internal carotid artery system. This system is responsible for 
approximately 70% of the total CBF. The other system is the vertebral artery sys-
tem, which is responsible for approximately 30% of the total CBF. These two major 
blood systems converge at Willis’ circle, which allows communication between 
the left and right brain hemispheres, and branch out into the whole brain through 
cerebral arteries [66]. The most common structural feature of cerebral vessels is the 
blood–brain barrier (BBB), which comprises tight junctions and adherens junctions 
[5]. These tight junctions exist between endothelial cells, the basal membrane, 
pericytes, and the astrocyte end feet [67].
The BBB is important because it prevents harmful molecules from entering 
the brain tissue from the systemic circulation. Accordingly, a malfunction in BBB 
permeability has been reported in neurodegenerative disorders and cognitive 
decline that leads to dementia [68–70]. CBF is regulated in response to blood pres-
sure through cerebral autoregulation. It was demonstrated that there were minor 
differences between CBF and blood pressure (within 10 mmHg of blood pressure) 
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among healthy humans in the plateau region [71]. The report also suggested that 
hypertension and a higher pulsatile rate might disrupt cerebral autoregulation, 
which make subjects prone to neurodegenerative diseases because the aging brain is 
subject to hypoperfusion [71].
3.2 Cerebral vascular aging
Healthy functional cerebral vessels can coordinate with CBF and appropriately 
supply blood to the brain [65]. As aging progresses, however, cerebrovascular func-
tion declines, which can increase the possibility of ischemic stroke, intracerebral 
hemorrhages (ICHs), microbleeds, and cognitive decline [64]. Cerebrovascular 
aging has the following features, which can lead to age-related cerebrovascular 
diseases:
i. Endothelial senescence: many studies have shown the presence of senescent 
endothelial cells in aged cerebrovascular lesions, which is triggered by 
the accumulation of ROS [31] and modulated by inflammatory factors, as 
described above.
ii. Oxidative stress and inflammation: in vessels’ walls, ROS increase nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase activity associated 
with aging [7, 72, 73]. These findings have been reported in both nonclinical 
and clinical studies. It is also well known that the vasculature can be easily 
damaged by vasculopathy, including atherosclerosis [74–76].
iii. Microvascular rarefaction: this is a condition where the microvascular 
network and its density are reduced. Rarefaction has been detected in some 
brain subregions, particularly in the hippocampus. Since the hippocampus 
is involved in memory, it could lead to memory loss [77, 78]. Circulating 
endothelial progenitor cells have been shown to be diminished by aging, 
which is linked to white matter changes and a decline in cognitive function 
[79, 80].
iv. Arterial stiffness: this is a major characteristic of vascular aging. Vascular 
stiffness increases blood flow velocity and blood pressure. Arterial stiffness 
results in an increase in systolic pressure and a decrease in diastolic pressure.
v. Vascular lumen narrowness: the accumulation of toxic molecules in the ves-
sel walls makes the vascular lumen narrow. There have been clinical studies 
such as cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL) that have examined Notch3 molecules 
in cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy. The high-temperature requirement A serine peptidase 
1 (HTRA1) is also explored in cerebral autosomal recessive arteriopathy and 
leukoencephalopathy [81–83].
vi. CBF reduction: generally, hypoperfusion in the cerebral circulation is sug-
gested to lead to cognitive impairment [84]. In cases of mild hypoperfusion, 
synaptic plasticity is impaired by a reduction in protein synthesis during 
learning and memory consolidation [2]. Under severe hypoperfusion, there 
is failure in the formation of the action potential, disruption in the acid–base 
balance, occurrence of neuronal edema, and accumulation of neurotic 
molecules [85].
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With respect to neural activity, cerebrovascular reactivity (CVR) can be used 
to measure the response levels of brain blood vessels to various stimuli. Very recent 
evidence has shown that cerebral vessel contractility and dilation decrease as aging 
progresses and have effects on the neurovascular damage mediated by NO [86]. In 
addition, there is an induction of vasoconstrictive factors in the cerebral endothelium 
[87]. Since the vessel wall undergoes structural changes through the normal aging pro-
cess, it is a natural and frequently found phenomenon that the basement membrane 
becomes thicker but smooth muscle cells and elastin layer are thinner [88]. These dif-
ferent responses between young and old adults have been demonstrated using blood-
oxygen-level-dependent functional MRI (BOLD fMRI) data [89]. As a result of these 
collective findings, it is now considered that the vasculature plays a critical secondary 
cause in many neurodegenerative diseases, particularly in neurovascular dysfunction. 
Therefore, there needs to be an increase in recognition and a focus on cognitive decline 
after vascular damage to develop newer therapeutic approaches.
4. Aging and vessel-related cognitive decline
Dementia is an irreversible cognitive condition. According to a statistical report, 
7.7 million people are newly diagnosed with dementia every year [90]. Among 
these, patients with vascular cognitive impairment and dementia (VCID) compose 
over 20% of the total dementia patient population [91]. By 2030, the number of 
older people (>60 years of age) is predicted to increase by 56% compared to the 
number in 2015, and it will continue to grow year by year. Finally, by 2050, our 
society will become a superaged society, and it is evident that the prevalence of 
neurodegenerative diseases will increase. Cognitive-related diseases, such as AD or 
VaD, will increase by 45% in 2050 compared to 2015 [92].
Mild cognitive impairment (MCI) is included as a cognitive-related disease in 
the older population. Although MCI is also considered as a pre-step proceeding to 
dementia, patients with MCI still fortunately have a chance of recovery or at least 
have a chance to delay the progression of the disease. Therefore, new strategies are 
urgently needed to diagnose and treat patients with MCI. Some blood factors such 
as MCP-1 or IL-6 have been suggested to be biomarkers for estimating the progres-
sion in cognitive decline because the vascular blood factors are modified in patients 
with MCI [93]. Some clinical studies have shown that VCID occurs in 25–30% of 
aged people who have had a previous stroke [94, 95]. Stroke is known to be the 
second leading cause of cognitive dysfunction. Furthermore, a clinical history of 
stroke increases the risk of cognitive dysfunction up to fivefold [96, 97]. Therefore, 
the symptoms of poststroke dementia could be related to the occlusion site, occlu-
sion type, occlusion numbers, and lesion volume in the brain. There are studies that 
have shown that poststroke cognitive decline is related to the pathology of cerebro-
vascular disease and dementia, although the mechanisms involved in poststroke 
dementia are complex [90, 98].
Aging is complex and vulnerable to cognitive decline as well as brain disorders 
[99]. A recent study concluded that cognitive impairment in aged adults with 
depression is correlated with the SASP profile [100]. This study showed that the 
levels of the SASP were highest in participants with both late-life depression (LLD) 
and MCI (Figure 1). This study suggests that cognitive impairment in LLD is linked 
to an aging-specific molecular profile, which might be an indicator for aging people 
with LLD who develop dementia [100]. Recent clinical studies have reported that 
depression and cognitive impairment in aging are associated with the regulation of 
the SASP: immune-inflammatory response [101], proteostasis [102], signal trans-
duction, and oxidative stress [103].
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5. Conclusions
Clinically and pathologically, vessel diseases including atherosclerosis are 
important diseases in a rapidly aging world. Age-related cerebrovascular dysfunc-
tions result from multiple pathophysiological alterations. The clear one thing is 
that vascular aging and the aged brain vessels are vulnerable to damages and harm-
ful factors such as the SASPs. Once the cerebral vessels have experienced insults, 
cognitive decline is eventually followed. The source of insults can be SASP particu-
larly in the aging process. Despite efforts to develop therapeutic targets, it is not 
possible to identify the processes contributing to the onset of vascular disease and 
its progression of cognitive decline. Our aging society needed more fundamental 
approaches for treating aging-related neurodegenerative diseases containing 
dementia. Preferential treatment might be a preventive chance to neurodegenera-
tive diseases. In the present time when dementia becomes an important issue in 
public heath, economics, social aspects, as well as the political fields, it should be 
possible to develop preventing and also therapeutic strategies against progressive 
dementia with a careful focus on treating vascular health by modulating the SASP.
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Figure 1. 
Aging, cerebrovascular burden, and developing cognitive decline to vascular dementia. With aging, the number 
of resident senescent cells displaying SASP increases. The familial genetic backgrounds and vascular risk factors 
acquired through individual lifestyle or harmful habits, such as smoking, increase vulnerability to vascular 
damage and neuronal dysfunction. Combined with aging factors, such as SASP, during the aging process, 
vascular damage and neuronal diseases could lead to susceptibility to cognitive decline, which consequently 
contributes to the progression of vascular dementia. Abbreviations: SASP, senescence-associated secretory 
phenotype; APOE4, apolipoprotein E4; PSEN1, presenilin 1; VSMC, vascular smooth muscle cell; EC, 
endothelial cell.
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